Third-line erlotinib therapy versus best supportive care for advanced non-small cell lung cancer (NSCLC) in British Columbia (BC), Canada. Is it cost effective?: PD3-2-4
JOURNAL OF THORACIC ONCOLOGY（2007）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要